Drug Search Results
More Filters [+]

Tinlarebant

Alternative Names: tinlarebant, lbs-008, lbs008, lbs 008, bpn-14967, bpn14967, bpn 14967
Latest Update: 2024-09-10
Latest Update Note: News Article

Product Description

Tinlarebant as an oral daily treatment to target RBP4 (retinol binding protein 4), disrupting vitamin A (retinol) binding to RBP4 (Sourced from: )

Mechanisms of Action: RBP4 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Fast Track - Stargardt Disease *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: RBP4
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tinlarebant

Countries in Clinic: Australia, Belgium, China, Czech Republic, France, Germany, Hong Kong, Japan, Netherlands, Switzerland, Taiwan, United Kingdom, United States

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Geographic Atrophy|Macular Degeneration|Stargardt Disease

Phase 1: Keratoconjunctivitis Sicca

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PHOENIX

P3

Recruiting

Geographic Atrophy

2027-08-31

42%

DRAGON II

P3

Recruiting

Macular Degeneration|Stargardt Disease

2027-06-01

LBS-008-CT05

P3

Recruiting

Geographic Atrophy

2025-11-25

LBS-008-CT03

P3

Not yet recruiting

Stargardt Disease

2025-09-19

Recent News Events